Amarin Corporation announced the publication of new data in the Journal of the American Heart Association, detailing a post-hoc analysis from the REDUCE-IT study, which found that Icosapent Ethyl ...

Atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of morbidity and mortality worldwide. Cardiovascular (CV) risk reduction is important in patients at high risk for a first ...

In draft guidance, the health technology assessment (HTA) organisation has recommended Vazkepa (icosapent ethyl) as a treatment option for adult patients with high-risk cardiovascular disease and ...

The Medicines and Healthcare products Regulatory Agency (MHRA) granted a marketing authorisation for Vazkepa (icosapent ethyl) as a treatment to reduce risk of cardiovascular events in high-risk ...

Icosapent Ethyl is a synthetic derivate of the omega-3 fatty acid eicosapentaenoic acid (EPA), prescribed as an adjunct to diet to reduce hypertriglyceridemia in adults.

The data focus on the mechanistic activities of eicosapentaenoic acid (EPA), the active ingredient in Amarin’s icosapent ethyl product, VASCEPA/VAZKEPA, which is used to reduce cardiovascular ...